SRDX - SurModics Inc

SRDX - SurModics Inc

https://www.surmodics.com

Hold Momentum: Bearish

Recent News

Powered by Alpha Vantage

SRDX Stock Up Following Q3 Earnings Beat, Gross Margin Contracts

Zacks Commentary • 1 month ago • score: 0.05

Surmodics delivers third-quarter fiscal 2025 earnings beat with narrower loss, as revenue tops estimates despite lower SurVeil DCB sales.

SurModics ( SRDX ) Q3 Earnings and Revenues Beat Estimates

Zacks Commentary • 1 month, 1 week ago • score: 0.02

SurModics (SRDX) delivered earnings and revenue surprises of +128.57% and +4.29%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Surmodics ( SRDX ) Q3 EPS Turns Positive

Motley Fool • 1 month, 1 week ago • score: 0.15

Surmodics ( NASDAQ:SRDX ) , a medical device technology firm known for its vascular intervention products and performance coatings, released results for Q3 FY2025 on August 8, 2025. The core news was a beat on both the top ( GAAP revenue ) and bottom ( non-GAAP EPS ) lines.

QuidelOrtho ( QDEL ) Down 18% Since Last Earnings Report: Can It Rebound?

Zacks Commentary • 3 months, 1 week ago • score: 0.05

QuidelOrtho (QDEL) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Why Is SurModics ( SRDX ) Up 6% Since Last Earnings Report?

Zacks Commentary • 3 months, 2 weeks ago • score: 0.26

SurModics (SRDX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Are Options Traders Betting on a Big Move in Surmodics Stock?

Zacks Commentary • 4 months, 1 week ago • score: 0.05

Investors need to pay close attention to SRDX stock based on the movements in the options market lately.

SRDX Stock Down Following Q2 Earnings Miss, Gross Margin Contracts

Zacks Commentary • 4 months, 1 week ago • score: -0.02

Despite the strength in Pounce thrombectomy device platforms and strong IVD product sales, Surmodics' second-quarter fiscal 2025 results show weak performance.

Interval:

EMA1: EMA2:

AI Tools

Key Metrics

Trend: Downtrend

As of 2025-09-09 (Snapshot)

Surmodics, Inc. provides surface modification technologies for intravascular medical devices and chemical components for microarray and in vitro diagnostic immunoassay tests in the United States and internationally. The company is headquartered in Eden Prairie, Minnesota.

52W High

$40.38

52W Low

$26.00

MA Status:

50D: Below 200D: Below

Beta (~1 neutral, <0.9 lower risk)

1.37

Valuation

Rich

As of 2025-06-30 (Overview)

Trailing P/E (<15 better)

N/A

Forward P/E (<15 better)

208.33

EV/EBITDA (<8 favorable)

179.57

EV/Revenue (<3 favorable)

3.83

P/S (TTM) (<3 favorable)

3.83

P/B (<3 favorable)

4.16

Ownership

Institution‑heavy

Source: Overview

Insiders (1–5% typical)

3.40%

Institutions (25–75% balanced)

90.81%

Shares Outstanding

14,297,600

Float

12,268,500

Dividend Yield (2–6% sweet spot)

N/A

Ex‑Dividend Date

N/A

Income & Growth

Profitability: Weak

As of 2025-06-30 (Overview)

Revenue (TTM)

120,801,000

Gross Profit (TTM)

92,073,000

EPS (TTM)

-1.24

Profit Margin (>10% good)

-0.15%

Operating Margin (TTM) (higher better)

0.00%

ROE (TTM) (>15% strong)

-0.15%

EPS YoY (Quarterly) (>10% good)

4.36

Revenue YoY (Quarterly) (>8% good)

-0.03

Momentum

Bearish momentum

Value

-0.9609

Previous

-0.8862

Trend

Falling

Signal Cross

No cross

As of

Sep. 12, 2025